Fundraising Fox
Shattuck Labs
NASDAQ: STTKAustin, US · Founded 2016 · Delaware corporation · 6 known investors
Find your way into Shattuck Labs
Sign up to see every warm intro you have to Shattuck Labs
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Shattuck Labs team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases. It is built around proprietary protein-engineering platforms and a pipeline of immunotherapy drug candidates.
Founders & leadership
Shattuck Labs was founded in 2016 by Josiah Hornblower and Taylor.
T
TaylorCo-founder & Chief Executive Officer, Board Member
Board
WL
Walter LoewenbaumBoard director
Investors · 6
Hatteras Venture Partnerslisted by Hatteras Venture PartnersResearch Triangle · $500K – $4M
How we know: Hatteras Venture Partners's portfolio page · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
REDMILEreportedSan Francisco
How we know: the S-1 prospectus · Not right? Tell us
T. Rowe PricereportedBaltimore
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$165.4M disclosed across 5 of 6 rounds · 2016–2026
▶$83MraisedJun 2020 · 32 investors · BiotechnologyRule 506(b)
▶$83MraisedJun 2020 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- G. Walter LoewenbaumDirector
- Taylor SchreiberExecutive Officer, Director
- Charles DorranceDirector
- Victor StoneDirector
- Josiah HornblowerDirector
- George GolumbeskiDirector
- Mike LeeDirector
- Neil GibsonDirector
- Tyler BrousDirector
- Offering amount
- $83M
- Amount sold
- $83M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$25.4MraisedFeb 2020 · 71 investors · BiotechnologyRule 506(b)
▶$25.4MraisedFeb 2020 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Taylor SchreiberExecutive Officer, Director
- Josiah HornblowerExecutive Officer, Director
- G. Walter LoewenbaumDirector
- Tyler BrousDirector
- Chris HurffDirector
- Neil GibsonDirector
- Charles DorranceDirector
- George GolumbeskiDirector
- David G. LoweDirector
- Offering amount
- $50M
- Amount sold
- $25.4M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$46.6MraisedMay 2018 · 62 investors · BiotechnologyRule 506(b)
▶$46.6MraisedMay 2018 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Taylor SchreiberExecutive Officer, Director
- Tyler BrousDirector
- Josiah HornblowerExecutive Officer, Director
- Charles DorranceDirector
- Charles GolumbeskiDirector
- David G. LoweExecutive Officer, Director
- G. Walter LoewenbaumDirector
- Neil GibsonDirector
- Offering amount
- $47.3M
- Amount sold
- $46.6M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$7MraisedApr 2017 · 27 investors · BiotechnologyRule 506(b)
▶$7MraisedApr 2017 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- G. Walter LoewenbaumDirector
- Tyler BrousDirector
- Taylor SchreiberExecutive Officer, Director
- Neil GibsonDirector
- David G. LoweDirector
- Josiah HornblowerExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.4MraisedAug 2016 · 25 investors · BiotechnologyRule 506(b)
▶$3.4MraisedAug 2016 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Walter LoewenbaumDirector
- Josiah HornblowerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.4M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$679.4Mvaluation at IPOOct 2020 · $17.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies working in the same space as Shattuck Labs.
In the news
Frequently asked questions
- What does Shattuck Labs do?
- Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases. It is built around proprietary protein-engineering platforms and a pipeline of immunotherapy drug candidates.
- Who founded Shattuck Labs?
- Shattuck Labs was founded by Josiah Hornblower, Taylor in 2016.
- Who are Shattuck Labs's investors?
- Shattuck Labs's investors include EcoR1 Capital, Hatteras Venture Partners, OrbiMed, Rocky Point Ventures, REDMILE, T. Rowe Price.
- How much funding has Shattuck Labs raised?
- Shattuck Labs has disclosed $165.4M raised across 5 of its 6 known rounds.
- Where is Shattuck Labs headquartered?
- Shattuck Labs is headquartered in Austin, US.